WEgovy Real World Assessment of Weight Loss in Korea

NCT07280221 | Enrolling By Invitation

• 2 other identifiers: NN9536-7850U1111-1306-1595
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Conditions

Obesity

Outcome Measures

Primary Outcomes (1)

• Percentage change in body weight

  Percent (%)

  From baseline (week 0) to 24 weeks

Secondary Outcomes (29)

• Absolute change in body weight

  From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

• Percentage change in body weight

  From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

• Achievement in body weight reduction more than or equal to (≥) 5%

  From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

• Achievement in body weight reduction ≥ 10%

  From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

• Achievement in body weight reduction ≥ 15%

  From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

Study Arms (1)

Once weekly Wegovy

Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

Drug: Semaglutide

Interventions

Semaglutide DRUG

Semaglutide injection will be self-administered once weekly subcutaneously.

Once weekly Wegovy

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

You may qualify if:

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
• Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
• Male or female, aged ≥ 19 years at the time of signing the informed consent.

You may not qualify if:

• Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
• Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Daejeon Endo Internal Medicine Clinic

Daejeon, 35220, South Korea

Location

MeSH Terms

Conditions

Obesity

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency dept. 2834

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2025
• First Posted: December 12, 2025
• Study Start: November 10, 2025
• Primary Completion (Estimated): October 31, 2027
• Study Completion (Estimated): October 31, 2027
• Last Updated: December 12, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share

Locations

KR (1)